Investors Under Scrutiny: Pomerantz Law Investigates Altimmune Claims

Investor Alert: Pomerantz Law Firm Investigates Altimmune, Inc.

In recent news, the Pomerantz Law Firm has initiated an investigation focused on claims related to investors of Altimmune, Inc. (NASDAQ: ALT). This stems from allegations concerning possible securities fraud and other unlawful practices within the company, involving several officers and directors.

Overview of the Investigation

On June 26, 2025, Altimmune publicly announced topline results from an important clinical trial, the Phase 2b IMPACT trial concerning pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). Despite characterizing the results as "positive," the statement revealed some alarming statistics. Specifically, the trial reported fibrosis improvement effects were only 31.8% and 34.5% for the doses of pemvidutide at 1.2 mg and 1.8 mg, respectively, compared to 25.9% for the placebo group. Crucially, these differences were noted as statistically insignificant.

This announcement had serious repercussions for Altimmune's stock price, which plummeted by $4.10, representing a staggering 53.18% drop, leaving the stock valued at $3.61 per share by market close on the same day.

Impact on Investors

The significant decline in stock value has prompted existing shareholders to seek legal recourse, leading to the firm’s current investigation. Investors potentially affected are encouraged to contact Danielle Peyton at Pomerantz LLP for additional information and assistance regarding the investigation and any pending legal actions.

Pomerantz Law Firm’s Track Record

Pomerantz LLP is recognized as one of the leading entities in the realm of corporate, securities, and antitrust litigation. Established by Abraham L. Pomerantz, often referred to as the dean of the class-action movement, the firm has a rich history of advocating for victims of corporate malfeasance. With a robust global presence, including offices in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz has successfully recovered millions of dollars for class members over the last 85 years, a tradition that continues into the present.

What’s Next for Altimmune Investors?

Investors are advised to be vigilant and stay informed about further developments regarding the investigation into Altimmune. The outcome could have significant financial implications not only for the company but also for shareholders who may have been misled by potentially flawed information. They should also keep tabs on future announcements from both Altimmune and the Pomerantz Law Firm as the investigation unfolds.

Conclusion

For anyone invested in Altimmune, it’s crucial to assess your rights, understand the ongoing investigation, and consider potential steps moving forward. The Pomerantz Law Firm’s inquiry could lead to significant revelations and ramifications for the involved parties. Shareholders are encouraged to reach out to the firm for legal advice and possible representation.

Whether you're an investor or just interested in corporate governance, the unfolding story of Altimmune serves as a critical case study in the challenges of maintaining integrity in the biotech investment landscape.